Endocrine and metabolic disorders in β-thalassemia major patients

Caspian Journal of Internal Medicine

Volumn 3, Issue 3, 2012, Pages 466-472

  Saffari, Fatemeh ^a   Mahyar, Abolfazl ^a   Jalilolgadr, Shabnam ^a  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Major thalassemia; Osteopenia; Osteoporosis; Puberty

Indexed keywords

25 HYDROXYVITAMIN D; GLUCOSE;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; BONE DENSITY; BONE RADIOGRAPHY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGONADISM; HYPOPARATHYROIDISM; HYPOTHYROIDISM; IMPAIRED GLUCOSE TOLERANCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; OSTEOPENIA; OSTEOPOROSIS; PHYSICAL EXAMINATION; PUBERTY DISORDERS; SHORT STATURE; THALASSEMIA MAJOR; VITAMIN D DEFICIENCY;

EID: 84865277643     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127: 127-39.
2. Karimi M, Ghiam AF, Hashemi A, et al. Bone mineral density in beta-thalassemia major and intermedia. Indian Pediatr 2007; 44: 29-32.
3. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, et al. Bone mineral density, biochemical and hormonal profiles in suboptimally treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol (Oxf) 2003; 58: 273-9.
4. Calleja EM, Shen JY, Lesser M, et al. Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience. Ann N Y Acad Sci 1998; 850: 469-70.
5. Bielinski BK, Darbyshire P, Mathers L, Boivin CM, Shaw NJ. Bone density in the Asian thalassaemic population: a cross-sectional review. Acta Paediatr 2001; 90: 1262-6.
6. Arjmand Rafsanjani Kh, Razzaghy-Azar M, Zahedi-Shoolami L, et al. Bone Mineral Density in β Thalassemia Major and Intermedia, Correlation with Biochemical and Hormonal Profiles. Iran J blood cancer 2009; 1: 121-7.
7. Filosa A, Di Maio S, Vocca S, et al. Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis. Acta Paediatr 1997; 86: 342-6.
8. El-Edel RH, Ghonaim MM, Abo-Salem OM, EI-Nemr FM. Bone mineral density and vitamin D receptor polymorphism in beta-thalassemia major. Pak J Pharm Sci 2010; 23: 89-96.
9. Lifshitz F, Botero D. Worrisome growth. In: Lifshitz F. Pediatric Endocrinology. 5th ed. New York: Informa Healthcare 2007; pp: 1-46. Vol 2.
10. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis child 1969; 44: 291-303.
11. Marshall WA, Tanner JM. Variations in the pattern of pubertal changes in boys. Arch Dis child 1970; 45: 13-23.
12. Kyriakou A, Skordis N. Thalassaemia and aberrations of growth and puberty. Mediterr J Hematol Infect Dis 2009; 1: e2009003.
13. Cappellini M, Cohen A, Eleftheriou A, Piga A, Porter J. Endocrine complications in thalassaemia major. In: Thalasemia International federation. Guidelines for the clinical management of Thalassemia. 1st ed. Nicosia, Cyprus: TIF 2000; pp: 41-9.
14. Evered DC, Ormston BJ, Smith PA, Hall R, Bird T. Grades of hypothyroidism. Br Med J 1973; 1: 657-62.
15. Binkley N, Ramamurthy R, Krueger D. Low vitamin D status: definition, prevalence, consequences, and correction. Endocrinol Metab Clin North Am 2010; 39: 287-301.
16. Wonke B. Clinical management of beta-thalassemia major. Semin Hematol 2001; 38: 350-9.
17. Vogiatzi MG, Autio KA, Mait JE, et al. Low bone mineral density in adolescents with beta-thalassemia. Ann N Y Acad Sci 2005; 1054: 462-6.
18. Landau H, Matoth I, Landau-Cordova Z, et al. Crosssectional and longitudinal study of the pituitary-thyroid axis in patients with thalassemia major. Clin Endocrinol (Oxf) 1993; 38: 55-61.
19. Viprakasit V, Lee-Lee C, Chong QT, Lin KH, Khuhapinant A. Iron chelation therapy in the management of thalassemia: the Asian perspectives. Int J Hematol 2009; 90: 435-45.
20. Porter JB. Monitoring and treatment of iron overload: state of the art and new approaches. Semin Hematol 2005; 42: s14-8.
21. Ho WL, Chung KP, Yang SS, et al. A pharmacoeconomic evaluation of deferasirox for treating patients with iron overload caused by transfusion-dependent thalassemia in Taiwan. J Formosan Med Assoc 2012; xx: 1-9. [In press]
22. De Sanctis V, Eleftheriou A, Malaventura C Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev 2004; 2: 249-55.
23. Multicentre study on prevalence of endocrine complications in thalassaemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Clin Endocrinol (Oxf) 1995; 42: 581-6.
24. Mahachoklertwattana P, Sirikulchayanonta V, Chuansumrit A, et al. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003; 88: 3966-72.
25. Rosenbloom AL. Idiopathic short stature: conundrums of definition and treatment. Int J Pediatr Endocrinol 2009; 2009: 470378.
26. Shamshirsaz AA, Bekheirnia MR, Kamgar M, et al. Metabolic and endocrinologic complications in betathalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003; 123: 4.
27. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988; 318: 809-14.
28. Anapliotou ML, Kastanias IT, Psara P, et al. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol (Oxf) 1995; 42: 279-87.
29. Magro S, Puzzonia P, Consarino C, et al. Hypothyroidism in patients with thalassemia syndromes. Acta Haematol 1990; 84: 72-6.
30. Depaz G, Deville A, Coussement N, Manassero J, Mariani R. Thyroid function in thalassemia major. Ann Pediatr (Paris) 1985; 32: 809-11. [In French]
31. De Sanctis V, Vullo C, Katz M, et al. Endocrine complications in thalassaemia major. Prog Clin Biol Res 1989; 309: 77-83.
32. Vullo C, De Sanctis V, Katz M, et al. Endocrine abnormalities in thalassemia. Ann N Y Acad Sci 1990; 612: 293-310.
33. Johanson NA. Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am 1990; 21: 191-8.
34. Christoforidis A, Kazantzidou E, Tsatra I, et al. Normal lumbar bone mineral density in optimally treated children and young adolescents with beta-thalassaemia major. Hormones (Athens) 2007; 6: 334-40.
35. Angastiniotis M, Pavlides N, Aristidou K, et al. Bone pain in thalassaemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab 1998; 11: 779-84.
36. Danesi L, Cherubini R, Ciceri L, et al. Evaluation of spine and hip bone density by DXA and QCT in thalassemic patients. J Pediatr Endocrinol Metab 1998; 11: 961-2.
37. Kwan EY, Lee AC, Li AM, et al. A cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong. J Paediatr Child Health 1995; 31: 83-7.
38. Chern JP, Lin KH, Lu MY, et al. Abnormal glucose tolerance in transfusion-dependent beta-thalassemic patients. Diabetes Care 2001; 24: 850-4.
39. Yazigi A, Maalouf G, Inati-Khoriati A, Tamim H, Saab C. Bone mineral density in beta - thalassemic Lebanese children. J Musculoskelet Neuronal Interact 2002; 2: 463-8.
40. Rioja L, Girot R, Garabédian M, Cournot - Witmer G. Bone disease in children with homozygous betathalassemia. Bone Miner 1990; 8: 69-86.
41. De Virgiliis S, Congia M, Frau F, et al. Deferoxamineinduced growth retardation in patients with thalassemia major. J Pediatr 1988; 113: 661-9.
42. de Vernejoul MC, Girot R, Gueris J, et al. Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J Clin Endocrinol Metab 1982; 54: 276-81.
43. Moulas A, Challa A, Chaliasos N, Lapatsanis PD. Vitamin D metabolites (25-hydroxyvitamin D, 24,25-dihydroxyvitamin D and 1, 25-dihydroxyvitamin D) and osteocalcin in beta-thalassaemia. Acta Paediatr 1997; 86: 594-9.
44. Praticò G, Di Gregorio F, Caltabiano L, et al. Bone metabolism markers in thalassemia. Pediatr Med Chir 2001; 23: 35-9. [In Italian]